TBK1 and hepatocellular carcinoma: As shown in Figure 5, overexpression of TBK1 induced the resistance of HCC cells to sorafenib; the antitumor effect of sorafenib significantly decreased (the IC50 value of the indicated concentrations of sorafenib increased from 1.25 ± 0.75 mg/kg to >2 mg/kg for tumor volumes and from 1.03 ± 0.42 mg/kg to >2 mg/kg for tumor weights).